OSTX9:00 AMOS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Programostherapies.com
OSTX7:40 AMOS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcomaostherapies.com
OSTX6:00 AMOS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic OsteosarcomaTrial Start • Phase 3Trial initiation Wed, Sep 30, 2026ostherapies.com
OSTX6:00 AMOS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic OsteosarcomaTrial Results • Phase 2MIB Agents Factor 2026 Osteosarcoma Conference presentation Thu, Jun 25, 2026ostherapies.com
OSTX7:20 AMOS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery WorldPresentation / Abstract • Phase 2ASCO presentation Thu, May 28, 2026ostherapies.com
OSTX7:40 AMOS Therapies to Attend Upcoming Medical, Financial and Industry ConferencesPresentation / Abstract • Phase 2ASCO 2026 2.5-Year OS Data Announcement Fri, May 29, 2026, 7:40 AM EDTGostherapies.com
OSTX6:30 AMOS Therapies Reports First Quarter 2026 Financials and Provides Business UpdatePresentation / Abstract • Phase 2ASCO 2026 data release Fri, Jun 5, 2026ostherapies.com
OSTX4:05 PMOS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026ostherapies.com
OSTX7:30 AMOS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisorostherapies.com
OSTX6:00 AMOS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic OsteosarcomaResults Call • Phase 2Call Thu, Apr 30, 2026, 8:30 AM ETostherapies.com
OSTX4:01 PMOS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ETResults CallCall Thu, Apr 30, 2026, 8:30 AM ETostherapies.com
OSTX7:20 AMOS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenesostherapies.com